SK111797A3 - Using alendronate for lessening the risk of non-vertebral bone fractures - Google Patents

Using alendronate for lessening the risk of non-vertebral bone fractures Download PDF

Info

Publication number: SK111797A3
Authority: SK; Slovakia
Prior art keywords: alendronate; fractures; risk; years; administered
Prior art date: 1995-02-17

Application number

SK1117-97A

Other languages

English (en)

Slovak (sk)

Inventor

Arthur C Ii Santora

David B Karpf

Deborah R Shapiro

William J Polvino

Desmond E Thompson

Ashley J Yates

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-17

Filing date

1996-02-13

Publication date

1998-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27013155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK111797(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-02-13 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1998-02-04 Publication of SK111797A3 publication Critical patent/SK111797A3/sk

Links

OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title claims abstract description 30
229940062527 alendronate Drugs 0.000 title claims abstract description 29
208000010392 Bone Fractures Diseases 0.000 title description 8
206010041569 spinal fracture Diseases 0.000 claims abstract description 25
208000001132 Osteoporosis Diseases 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims 1
206010017076 Fracture Diseases 0.000 abstract description 23
229940122361 Bisphosphonate Drugs 0.000 abstract description 2
150000004663 bisphosphonates Chemical class 0.000 abstract description 2
229940068196 placebo Drugs 0.000 description 15
239000000902 placebo Substances 0.000 description 15
239000000203 mixture Substances 0.000 description 11
230000001186 cumulative effect Effects 0.000 description 7
235000002639 sodium chloride Nutrition 0.000 description 7
210000000988 bone and bone Anatomy 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000000034 method Methods 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
-1 alkali metal salts Chemical class 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000011282 treatment Methods 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
150000004673 fluoride salts Chemical class 0.000 description 2
210000004394 hip joint Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
210000003857 wrist joint Anatomy 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
101100246550 Caenorhabditis elegans pyr-1 gene Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020100 Hip fracture Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical class CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
208000016097 disease of metabolism Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000001624 hip Anatomy 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960005431 ipriflavone Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000009245 menopause Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000001009 osteoporotic effect Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
238000011176 pooling Methods 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK1117-97A 1995-02-17 1996-02-13 Using alendronate for lessening the risk of non-vertebral bone fractures SK111797A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39046295A	1995-02-17	1995-02-17
US41963195A	1995-04-10	1995-04-10
PCT/US1996/001932 WO1996025165A1 (fr)	1995-02-17	1996-02-13	Procede de diminution des risques de fractures osseuses autres que les fractures vertebrales

Publications (1)

Publication Number	Publication Date
SK111797A3 true SK111797A3 (en)	1998-02-04

Family

ID=27013155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1117-97A SK111797A3 (en)	1995-02-17	1996-02-13	Using alendronate for lessening the risk of non-vertebral bone fractures

Country Status (13)

Country	Link
US (1)	US5804570A (fr)
EP (1)	EP0809502A4 (fr)
JP (1)	JPH10504839A (fr)
KR (1)	KR19980702210A (fr)
CN (1)	CN1181012A (fr)
AU (1)	AU690431B2 (fr)
CA (1)	CA2212996A1 (fr)
EA (1)	EA000347B1 (fr)
HU (1)	HUP9802066A3 (fr)
NZ (1)	NZ303022A (fr)
PL (1)	PL321835A1 (fr)
SK (1)	SK111797A3 (fr)
WO (1)	WO1996025165A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
US6432932B1 (en)	1997-07-22	2002-08-13	Merck & Co., Inc.	Method for inhibiting bone resorption
US5994329A (en) *	1997-07-22	1999-11-30	Merck & Co., Inc.	Method for inhibiting bone resorption
US6331533B1 (en)	1998-11-16	2001-12-18	Merck & Co., Inc.	Method for inhibiting dental resorptive lesions
US6416737B1 (en) *	1998-11-19	2002-07-09	Board Of Trustees Of The University Of Arkansas	Increasing bone strength with selected bisphosphonates
KR100317935B1 (ko) *	1999-10-20	2001-12-22	유승필	대사성 골질환 치료용 약제조성물 및 이의 제조방법
CN1196480C (zh) *	2001-07-03	2005-04-13	北京巨能亚太生命科学研究中心	L－苏糖酸钙在制备预防或治疗骨折的药物中的用途
CA2444718A1 (fr) *	2001-05-02	2002-11-14	Novartis Ag	Methode d'administration de bisphosphonates par inhalation pour traiter ou prevenir la resorption osseuse et l'osteoporose
US20040052843A1 (en) *	2001-12-24	2004-03-18	Lerner E. Itzhak	Controlled release dosage forms
EA006053B1 (ru) *	2001-12-24	2005-08-25	Тева Фармасьютикал Индастриес Лтд.	Твёрдая лекарственная форма, способ её изготовления и устройство
EP2316469A1 (fr)	2002-02-22	2011-05-04	Shire LLC	Système de distribution et méthodes de protection et d'administration de dextroamphetamine
WO2003086415A1 (fr) *	2002-04-05	2003-10-23	Merck & Co., Inc.	Procede d'inhibition de resorption osseuse a l'aide d'une formulation a base d'alendronate et de vitamine d
CA2763775C (fr) *	2002-05-10	2014-01-07	F. Hoffmann-La Roche Ag	Acide bisphosphonique pour le traitement et la prevention de l'osteoporose
US20040138180A1 (en) *	2002-10-03	2004-07-15	Barr Laboratories, Inc.	Bisphosphonate composition and process for the preparation thereof
US20040097468A1 (en) *	2002-11-20	2004-05-20	Wimalawansa Sunil J.	Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US20050261250A1 (en) *	2004-05-19	2005-11-24	Merck & Co., Inc.,	Compositions and methods for inhibiting bone resorption
US20060134190A1 (en) *	2004-12-16	2006-06-22	Banner Pharmacaps Inc.	Formulations of bisphosphonate drugs with improved bioavailability
GB201200868D0 (en)	2012-01-19	2012-02-29	Depuy Int Ltd	Bone filler composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3683080A (en) *	1970-08-28	1972-08-08	Procter & Gamble	Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
IT1201087B (it) *	1982-04-15	1989-01-27	Gentili Ist Spa	Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4761406A (en) *	1985-06-06	1988-08-02	The Procter & Gamble Company	Regimen for treating osteoporosis
US4922007A (en) *	1989-06-09	1990-05-01	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) *	1990-06-20	1991-05-28	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
JPH0523134A (ja) *	1991-07-23	1993-02-02	Mitsubishi Kasei Corp	骨強度増強促進剤及びこれを含有する食品類
US5270365A (en) *	1991-12-17	1993-12-14	Merck & Co., Inc.	Prevention and treatment of periodontal disease with alendronate
EP0600834A1 (fr) *	1992-11-30	1994-06-08	Ciba-Geigy Ag	Utilisation de dérivés de l'acide méthanediphosphonique pour la fabrication d'un médicament pour le traitement de fractures
US5366965A (en) *	1993-01-29	1994-11-22	Boehringer Mannheim Gmbh	Regimen for treatment or prophylaxis of osteoporosis
US5403829A (en) *	1993-03-24	1995-04-04	Leiras Oy	Use of bisphosphonates in endo-osteal bone surgery
JPH0717854A (ja) *	1993-04-05	1995-01-20	Koichi Shudo	抗骨疾患剤
US5431920A (en) *	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5462932A (en) *	1994-05-17	1995-10-31	Merck & Co., Inc.	Oral liquid alendronate formulations
US5616571A (en) *	1995-06-06	1997-04-01	Merck & Co., Inc.	Bisphosphonates prevent bone loss associated with immunosuppressive therapy

1996
- 1996-02-13 JP JP8525087A patent/JPH10504839A/ja active Pending
- 1996-02-13 EA EA199700183A patent/EA000347B1/ru not_active IP Right Cessation
- 1996-02-13 CA CA002212996A patent/CA2212996A1/fr not_active Abandoned
- 1996-02-13 NZ NZ303022A patent/NZ303022A/xx unknown
- 1996-02-13 AU AU49227/96A patent/AU690431B2/en not_active Ceased
- 1996-02-13 HU HU9802066A patent/HUP9802066A3/hu unknown
- 1996-02-13 PL PL96321835A patent/PL321835A1/xx unknown
- 1996-02-13 CN CN96193109A patent/CN1181012A/zh active Pending
- 1996-02-13 KR KR1019970705605A patent/KR19980702210A/ko not_active Ceased
- 1996-02-13 SK SK1117-97A patent/SK111797A3/sk unknown
- 1996-02-13 EP EP96905482A patent/EP0809502A4/fr not_active Withdrawn
- 1996-02-13 WO PCT/US1996/001932 patent/WO1996025165A1/fr not_active Ceased
1997
- 1997-06-03 US US08/867,987 patent/US5804570A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JPH10504839A (ja)	1998-05-12
AU4922796A (en)	1996-09-04
NZ303022A (en)	2000-07-28
WO1996025165A1 (fr)	1996-08-22
PL321835A1 (en)	1997-12-22
EA000347B1 (ru)	1999-04-29
US5804570A (en)	1998-09-08
EP0809502A4 (fr)	2001-12-05
CA2212996A1 (fr)	1996-08-22
EP0809502A1 (fr)	1997-12-03
HUP9802066A2 (hu)	2000-06-28
EA199700183A1 (ru)	1997-12-30
MX9706277A (es)	1997-11-29
AU690431B2 (en)	1998-04-23
HUP9802066A3 (en)	2001-02-28
KR19980702210A (ko)	1998-07-15
CN1181012A (zh)	1998-05-06

Publication	Publication Date	Title
SK111797A3 (en)	1998-02-04	Using alendronate for lessening the risk of non-vertebral bone fractures
Valente et al.	1994	Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass
US11896567B2 (en)	2024-02-13	Combination composition
EA000964B1 (ru)	2000-08-28	Способ лечения или предупреждения остеопороза
US5393531A (en)	1995-02-28	Process for the preparation of a pharmaceutical formulation containing at least two different active substances and use of such a formulation
WO2009048289A2 (fr)	2009-04-16	Composition pharmaceutique pour traiter une infection par le virus de l'hépatite c comprenant un inhibiteur de la hmg-coa réductase et de l'acide biliaire
SK111697A3 (en)	1998-02-04	Using alendronate for lessening the risk of vertebral fractures
KR101318067B1 (ko)	2013-10-15	란탄 화합물을 이용한 만성 신장 질환 (ｃｋｄ) 치료 방법
AU703887B2 (en)	1999-04-01	Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
AU709196B2 (en)	1999-08-26	Use of alendronate for the prevention of osteoporosis
US20020169148A1 (en)	2002-11-14	Use of alendronate for the prevention of osteoporosis
CZ259097A3 (en)	1997-11-12	Pharmaceutical preparation for reducing risk of bone fractures
AU696097C (en)	1999-03-25	Bisphosphonates prevent bone loss associated with immunosuppressive therapy
CN1187130A (zh)	1998-07-08	用二磷酸盐预防与免疫抑制疗法有关的骨损失
MXPA97009906A (en)	1998-10-15	Use of bisphosphonates to prepare compositions to prevent loss of associated bone conterapia immunosupres